Shanghai Heartcare Medical Technology Corp. Ltd. Class H (6609) AI Stock Analysis

• Market Cap: HK$2.37B
• Dividend Yield: N/A
• Average Volume (3M): 127.28K
• Price to Earnings (P/E): 50.9
• Beta (1Y): 1.25
• Revenue Growth: 32.93%
• EPS Growth: N/A
• Country: HK
• Employees: 344
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 1.47
• Shares Outstanding: 31,565,804
• 10 Day Avg. Volume: 119,990
• 30 Day Avg. Volume: 127,280
• PEG Ratio: 0.67
• Price to Book (P/B): 0.73
• Price to Sales (P/S): 2.80
• P/FCF Ratio: -92.80
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 60 Neutral
• Price Target: HK$63.00 ▲(15.38% Upside)

The score is supported primarily by solid financial footing (low leverage) and decent revenue growth, alongside positive technical momentum (price above key moving averages, positive MACD). These positives are tempered by expensive valuation (P/E 45.47), mixed profitability signals (negative EBIT margin), and somewhat stretched momentum indicators (RSI 70.87).

Positive Factors

Revenue Growth

Strong revenue growth indicates expanding market presence and product demand, supporting long-term business sustainability and potential for increased market share.

Balance Sheet Health

A strong balance sheet with low leverage enhances financial stability, providing the company with flexibility to invest in growth opportunities and withstand economic fluctuations.

Market Demand

Growing demand for cardiovascular solutions supports long-term revenue potential, as the company is well-positioned to capitalize on industry trends and healthcare needs.

Negative Factors

Profitability Challenges

Ongoing net losses and cash flow issues indicate challenges in achieving profitability, which could hinder the company's ability to reinvest in growth and innovation.

Cash Flow Management

Negative cash flow suggests inefficiencies in operations and cash management, potentially limiting the company's ability to fund new projects and maintain financial health.

Operational Inefficiencies

Negative EBIT and EBITDA margins reflect operational inefficiencies, which may impact the company's ability to improve profitability and compete effectively in the market.

Shanghai Heartcare Medical Technology Corp. Ltd. Class H Business Overview & Revenue Model

Company Description

Shanghai HeartCare Medical Technology Corporation Limited engages in the research, development, manufacture, and sale of neuro-interventional medical devices worldwide. The company offers ischemic stroke thrombectomy, intracranial stenosis treatment, ischemic stroke prevention, hemorrhagic stroke treatment, and vascular access devices. Its products are used for the treatment and prevention of ischemic stroke, including acute ischemic stroke and intracranial stenosis, as well as for the treatment of hemorrhagic stroke. The company was formerly known as Shanghai Care Medical Technology Corporation Limited. Shanghai HeartCare Medical Technology Corporation Limited was incorporated in 2016 and is headquartered in Shanghai, the People's Republic of China.

How the Company Makes Money

Shanghai Heartcare Medical Technology Corp. Ltd. generates revenue through multiple streams, primarily by selling its proprietary medical devices and diagnostic equipment to hospitals, clinics, and healthcare providers. The company also earns money through software solutions that integrate with its devices, offering analytics and data management services. Additionally, it may have revenue from partnerships with healthcare institutions for research and development, as well as collaborations with pharmaceutical companies for integrated therapeutic solutions. The company benefits from ongoing training and support services provided to healthcare professionals, which also contributes to its revenue. Furthermore, the increasing demand for cardiovascular health solutions in the aging population and the growing prevalence of heart disease enhances the company's earning potential.

Shanghai Heartcare Medical Technology Corp. Ltd. Class H Financial Statement Overview

Summary

Shanghai Heartcare Medical Technology Corp. Ltd. Class H shows promising revenue growth and a strong balance sheet with low leverage. However, profitability metrics such as net profit margin and EBIT margin indicate areas for improvement. The cash flow situation is improving, with significant growth in free cash flow, but operational cash flow coverage remains a concern. Overall, the company is on a positive trajectory but needs to focus on enhancing profitability and operational efficiency.

Income Statement

The company has shown a positive revenue growth rate of 9.31% in the TTM, indicating a strong upward trajectory in sales. Gross profit margin remains healthy at 67.49%, reflecting efficient cost management. However, the net profit margin is relatively low at 12.67%, suggesting room for improvement in profitability. The EBIT margin is negative, which is a concern, but the EBITDA margin is positive, indicating some operational efficiency.

Balance Sheet

The balance sheet is strong with a low debt-to-equity ratio of 0.041, indicating low financial leverage and risk. Return on equity is modest at 3.90%, showing some profitability for shareholders. The equity ratio is high, suggesting a stable financial structure with a significant portion of assets financed by equity.

Cash Flow

The company has achieved significant free cash flow growth of 162.48% in the TTM, which is a positive sign of improving cash generation. The operating cash flow to net income ratio is 0.61, indicating that operating cash flows are not fully covering net income. The free cash flow to net income ratio is 0.73, suggesting that a substantial portion of net income is being converted into free cash flow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	334.94M	277.90M	232.34M	183.03M	90.09M	14.56M
Gross Profit	226.03M	181.72M	151.79M	124.33M	54.95M	7.09M
EBITDA	22.90M	21.87M	-68.50M	-167.31M	-183.34M	-206.19M
Net Income	42.44M	-13.62M	-94.01M	-200.38M	-194.22M	-213.66M
Balance Sheet
Total Assets	1.25B	1.21B	1.20B	1.31B	1.50B	773.63M
Cash, Cash Equivalents and Short-Term Investments	718.20M	713.72M	721.14M	870.12M	1.22B	632.42M
Total Debt	45.91M	35.75M	36.38M	50.69M	41.94M	24.69M
Total Liabilities	137.78M	144.00M	125.60M	147.08M	132.10M	82.60M
Stockholders Equity	1.11B	1.06B	1.08B	1.17B	1.37B	681.37M
Cash Flow
Free Cash Flow	30.56M	-8.39M	-137.72M	-304.01M	-260.33M	-90.42M
Operating Cash Flow	41.60M	-3.23M	-88.41M	-266.77M	-205.85M	-74.81M
Investing Cash Flow	-194.07M	10.80M	-125.45M	44.84M	-161.10M	-4.53M
Financing Cash Flow	-11.15M	-12.38M	-21.48M	-24.75M	821.25M	686.22M

Shanghai Heartcare Medical Technology Corp. Ltd. Class H Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 54.60
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6609, the sentiment is Positive. The current price of 54.6 is above the 20-day moving average (MA) of 53.00, above the 50-day MA of 50.36, and above the 200-day MA of 45.59, indicating a bullish trend. The MACD of 2.79 indicates Negative momentum. The RSI at 70.00 is Neutral, neither overbought nor oversold. The STOCH value of 62.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:6609.

Shanghai Heartcare Medical Technology Corp. Ltd. Class H Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
6609	60 Neutral	HK$2.37B	50.88	3.84%	―	32.93%	―
1302	57 Neutral	HK$7.17B	93.26	1.98%	―	3.42%	-70.82%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
2160	46 Neutral	HK$7.64B	545.45	0.22%	―	-4.38%	―
2235	44 Neutral	HK$3.15B	-103.74	-1.39%	―	49.86%	80.35%
2500	41 Neutral	HK$1.12B	-1.59	-26.80%	―	-8.56%	-14.84%
9996	39 Underperform	HK$4.43B	-18.06	-11.20%	―	29.25%	9.02%

Shanghai Heartcare Medical Technology Corp. Ltd. Class H Corporate Events

Shanghai HeartCare Calls 2026 Class Meeting to Approve Non-Pre-Emptive Domestic Share Issuance

Shanghai HeartCare Medical Technology Corporation Limited has convened a 2026 class meeting of its unlisted shareholders on 16 January 2026 in Shanghai to seek approval for a proposed issuance of new domestic shares under a specific mandate. Shareholders will vote on the issuance itself, ratification of a subscription agreement with investor Zhang Han, authorization for the board to handle all matters related to the issuance, and confirmation that the new shares will be issued on a non-pre-emptive basis. The move, if approved, would provide the company with additional domestic capital and further flexibility in its capital structure, potentially diluting existing holdings of unlisted shareholders while supporting funding for ongoing business development.

The most recent analyst rating on (HK:6609) stock is a Hold with a HK$47.00 price target. To see the full list of analyst forecasts on Shanghai Heartcare Medical Technology Corp. Ltd. Class H stock, see the HK:6609 Stock Forecast page.

Shanghai HeartCare Calls 2026 Extraordinary Meeting to Revamp Governance and Approve New Share Issue

Shanghai HeartCare Medical Technology Corporation Limited has called its first extraordinary general meeting of 2026 for 16 January in Shanghai, where shareholders will vote on a series of governance, capital and structural measures. The agenda includes amendments to the board and shareholders’ meeting rules of procedure, adoption of a management of proceeds policy, approval of a domestic share issuance under a specific mandate and related subscription agreement, as well as granting the board broad authority over the issuance and allowing it to proceed on a non-pre-emptive basis. Shareholders will also consider abolishing the Board of Supervisors and amending the Articles of Association, signalling a potential reshaping of the company’s corporate governance framework and capital structure with implications for shareholder rights and oversight.

The most recent analyst rating on (HK:6609) stock is a Hold with a HK$47.00 price target. To see the full list of analyst forecasts on Shanghai Heartcare Medical Technology Corp. Ltd. Class H stock, see the HK:6609 Stock Forecast page.

Shanghai HeartCare Calls H Shareholders’ Meeting to Approve Domestic Share Issuance Plan

Shanghai HeartCare Medical Technology Corporation Limited has convened a 2026 first class meeting of its H shareholders to be held in Shanghai on 16 January 2026, immediately after an extraordinary general meeting, to vote on several key capital-related matters. H shareholders will consider a proposed issuance of domestic shares under a specific mandate, the ratification of a subscription agreement with investor Zhang Han, authorization for the board to handle all matters related to the issuance, and approval for the issuance to proceed on a non-pre-emptive basis, a move that could broaden the company’s funding channels but may dilute existing shareholdings; the notice also sets out procedural requirements for proxy appointments, share transfer cut-off dates and voting eligibility, underscoring the corporate governance steps around this potential capital-raising exercise.

The most recent analyst rating on (HK:6609) stock is a Hold with a HK$47.00 price target. To see the full list of analyst forecasts on Shanghai Heartcare Medical Technology Corp. Ltd. Class H stock, see the HK:6609 Stock Forecast page.

Shanghai HeartCare Sets January Meetings on Share Issuance and Articles Changes

Shanghai HeartCare Medical Technology Corporation Limited has scheduled an extraordinary general meeting and a class meeting of H shareholders for 16 January 2026 to consider, among other matters, the proposed issuance of domestic shares under a specific mandate and amendments to its articles of association. To determine eligibility to attend and vote at these meetings, the H share register will be closed from 13 to 16 January 2026, with no share transfers registered during this period, and shareholders must ensure relevant transfer documents are lodged with the company’s Hong Kong share registrar by 12 January 2026, underscoring the procedural steps ahead of a potentially significant capital and governance move for the company.

The most recent analyst rating on (HK:6609) stock is a Hold with a HK$47.00 price target. To see the full list of analyst forecasts on Shanghai Heartcare Medical Technology Corp. Ltd. Class H stock, see the HK:6609 Stock Forecast page.

Shanghai Heartcare Revamps Share Incentive Program to Boost Efficiency

Shanghai Heartcare Medical Technology Corp. Ltd. announced a change in its share incentive program by canceling previously granted share awards and issuing new ones. This move is aimed at motivating management personnel to maximize their efforts for the company’s success while also increasing efficiency and reducing administrative costs associated with the incentive schemes.

The most recent analyst rating on (HK:6609) stock is a Hold with a HK$47.00 price target. To see the full list of analyst forecasts on Shanghai Heartcare Medical Technology Corp. Ltd. Class H stock, see the HK:6609 Stock Forecast page.

Shanghai Heartcare Proposes Issuance of Domestic Shares to Boost Competitiveness

Shanghai Heartcare Medical Technology Corp. Ltd. has announced a proposed issuance of 1,000,000 domestic shares under a specific mandate, priced at HK$45.00 each, as part of a subscription agreement with Mr. Zhang. This move aims to enhance the company’s competitiveness and secure additional funds for its operations. The issuance is subject to shareholder approval and regulatory conditions, and a special resolution will be proposed at upcoming meetings to authorize the board to manage the issuance process.

The most recent analyst rating on (HK:6609) stock is a Hold with a HK$47.00 price target. To see the full list of analyst forecasts on Shanghai Heartcare Medical Technology Corp. Ltd. Class H stock, see the HK:6609 Stock Forecast page.

Shanghai HeartCare Proposes Governance Changes Amid New Regulatory Landscape

Shanghai HeartCare Medical Technology Corporation Limited has announced its intention to abolish its Supervisory Committee in favor of establishing an Audit Committee, in compliance with the new amendments to the Company Law of the People’s Republic of China effective July 1, 2024. This move is part of a broader effort to enhance corporate governance and align with updated regulatory requirements, which also includes proposed amendments to the company’s Articles of Association. These changes are subject to shareholder approval at an upcoming extraordinary general meeting.

The most recent analyst rating on (HK:6609) stock is a Hold with a HK$47.00 price target. To see the full list of analyst forecasts on Shanghai Heartcare Medical Technology Corp. Ltd. Class H stock, see the HK:6609 Stock Forecast page.